This is an open-label non-randomization trail. The study will have 3 cohorts. Cohorts 1 to 3 will run simultaneously with the same regimen. Cohort 1 will include 39 participants who have not received any previous therapy. In Cohort 2, 25 participants who have received only one previous therapy for their disease will be included. In Cohort 3, 25 participants who have received two or more prior therapies for their advanced disease will receive the experimental regimen.
This is a study of docetaxel, oxaliplatin and 5-Fluorouracil for advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal involvement and inoperable malignant bowel obstruction: the triplet regimen will be given as 1st, 2nd or later line treatment to participants. The primary study hypothesis is that the regimen will provide a clinically meaningful Bowel Obstruction Remission.